Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: The xelbevoct study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Berruti, Alfredo ^a   Fazio, Nicola ^b   Ferrero, Anna ^c   Brizzi, Maria P ^c   Volante, Marco ^c   Nobili, Elisabetta ^d   Tozzi, Lucia ^e   Bodei, Lisa ^c   Torta, Mirella ^c   D'Avolio, Antonio ^c   Priola, Adriano M ^f   Birocco, Nadia ^g   Amoroso, Vito ^a   Biasco, Guido ^d   Papotti, Mauro ^c   Dogliotti, Luigi ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

Author keywords

Bevacizumab; Capecitabine; Octreotide; Pancreatic endocrine tumor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; LONG ACTING DRUG; OCTREOTIDE; VASCULOTROPIN; VITAMIN D; TUMOR MARKER; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER PROGNOSIS; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY DYSFUNCTION; MALE; METASTATIC WELL TO MODERATELY DIFFERENTIATED NEUROENDOCRINE NEOPLASM; METRONOMIC DRUG ADMINISTRATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECTUM HEMORRHAGE; STOMATITIS; THROMBOSIS; VEIN THROMBOSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANAMNESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; LABORATORY TEST; LIFE EXPECTANCY; METASTASIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; TREATMENT RESPONSE; VITAMIN DEFICIENCY; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, METRONOMIC; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; TREATMENT OUTCOME;

EID: 84899085315     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-184     Document Type: Article

References (27)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND. Tumors of the Digestive System. World Health Organization Classification of Tumours. Pathology and Genetics 2010, Lyon: IARC Press.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification Tumours. Pathology and Genetics 2004 2004, Lyon: IARC Press.
3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9(1):61-72. 10.1016/S1470-2045(07)70410-2, 18177818.
4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 18:3063-3072.
5. Volante M, Righi L, Berruti A, Rindi G, Papotti M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch 2011, 458(4):393-402. 10.1007/s00428-011-1060-7, 21344263.
6. Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Macello E, Bodei L, Paganelli G, Delle Fave G, De Braud F. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev 2010, 36(Suppl 3):S87-S94.
7. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 15;31(2):169-188.
8. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 10;364(6):501-513.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, . RAD001 in Advanced Neuroendocrine Tumors Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 10;364(6):514-523. RAD001 in Advanced Neuroendocrine Tumors.
10. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 10;26(8):1316-1323.
11. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, . ECOG 2100 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 28:4672-4678. ECOG 2100.
12. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20(2):227-230.
13. Karachaliou N, Saloustros E, Vamvakas L, Mavroudis D, Georgoulias V. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. Ann Oncol 2010, 21(8):1729-1730. 10.1093/annonc/mdq328, 20601370.
14. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 19;357(3):266-281.
15. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009, 4(9):1523-1528. 10.2215/CJN.02010309, 19478099.
16. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436. 10.1038/nrc1369, 15170445.
17. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer 2009, 9:388-395. 10.1186/1471-2407-9-388, 2776604, 19886987.
18. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, . PROMID Study Group Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 1;27(28):4656-4663. PROMID Study Group.
19. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82. 10.1200/JCO.2007.12.1939, 18165643.
20. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with Bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905. 10.1200/JCO.2008.17.4789, 18794539.
21. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011, 1;29(7):934-943.
22. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, . and all other Frascati Consensus Conference participants European Neuroendocrine Tumor Society (ENETS) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449(4):395-401. 10.1007/s00428-006-0250-1, 1888719, 16967267, and all other Frascati Consensus Conference participants European Neuroendocrine Tumor Society (ENETS).
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10. 10.1016/0197-2456(89)90015-9, 2702835.
24. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010, 46(2):439-448. 10.1016/j.ejca.2009.11.001, 20006922.
25. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007, 50:69-77. 10.1053/j.ajkd.2007.04.015, 17591526.
26. Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, Berruti A. Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist 2011, 16(9):1215-1227. 10.1634/theoncologist.2011-0098, 3228169, 21835895.
27. Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010, 14(4):347-351.